GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » ROC %

Taisho Pharmaceutical Holdings Co (TSE:4581) ROC % : 1.12% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Taisho Pharmaceutical Holdings Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 1.12%.

As of today (2024-05-14), Taisho Pharmaceutical Holdings Co's WACC % is 0.00%. Taisho Pharmaceutical Holdings Co's ROC % is 1.75% (calculated using TTM income statement data). Taisho Pharmaceutical Holdings Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Taisho Pharmaceutical Holdings Co ROC % Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co ROC % Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 3.03 2.24 1.28 2.71

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.88 -0.23 4.15 2.67 1.12

Taisho Pharmaceutical Holdings Co ROC % Calculation

Taisho Pharmaceutical Holdings Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2023 is calculated as:

ROC % (A: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2022 ) + Invested Capital (A: Mar. 2023 ))/ count )
=23019 * ( 1 - 27.78% )/( (581690 + 646350)/ 2 )
=16624.3218/614020
=2.71 %

where

Taisho Pharmaceutical Holdings Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=10624 * ( 1 - 26.08% )/( (696890 + 700064)/ 2 )
=7853.2608/698477
=1.12 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taisho Pharmaceutical Holdings Co  (TSE:4581) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Taisho Pharmaceutical Holdings Co's WACC % is 0.00%. Taisho Pharmaceutical Holdings Co's ROC % is 1.75% (calculated using TTM income statement data). Taisho Pharmaceutical Holdings Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Taisho Pharmaceutical Holdings Co ROC % Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines